STA
MCRB icon

Summit Trail Advisors’s Seres Therapeutics MCRB Stock Holding History

Summit Trail Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$7.74K – 641
2024
Q1 		$7.74K Buy
+500
New +$10.8K ﹤0.01% 612

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Trail Advisors's MCRB Position: Q2 2024 in Review

Summit Trail Advisors sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 500 shares — an estimated $7.74K sold.

Summit Trail Advisors first reported a position in MCRB in Q1 2024 and held it in 1 quarter. The position peaked at $7.74K in Q1 2024. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • Summit Trail Advisors reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 500 Seres Therapeutics shares in Q2 2024, an estimated $7.74K.
  • Summit Trail Advisors first reported a position in Seres Therapeutics in Q1 2024 and held it in 1 quarter.
  • Summit Trail Advisors's Seres Therapeutics position peaked at $7.74K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Summit Trail Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.